Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 14/20 | 0.61 |
| ▸ | MAOB | P27338 | 14/20 | 0.61 |
| ▸ | PRKCI | P41743 | 1/20 | 0.61 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.54 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26016734 | 0.98 | MAOA (0.58) | MAOAMAOBPRKCIHSD17B1BAZ2B | |
| SCHEMBL4805957 | 0.89 | CASP1 (0.53) | MAOAMAOBPRKCIHSD17B1GRM5 | |
| SCHEMBL14013915 | 0.82 | MAOA (0.56) | MAOAMAOBPRKCIHSD17B1BAZ2B | |
| SCHEMBL6794989 | 0.81 | AKR1B1 (0.60) | MAOAMAOBPRKCIHSD17B1BAZ2B | |
| SCHEMBL8790426 | 0.80 | MAOA (0.54) | MAOAMAOBPRKCIHSD17B1BAZ2B | |
| SCHEMBL11272172 | 0.80 | MAOA (0.53) | MAOAMAOBPRKCIHSD17B1BAZ2B | |
| SCHEMBL7507446 | 0.80 | MAOA (0.53) | MAOAMAOBPRKCIHSD17B1BAZ2B | |
| SCHEMBL23162895 | 0.79 | AKR1B1 (0.61) | MAOAMAOBPRKCIHSD17B1BAZ2B | |
| SCHEMBL7640635 | 0.79 | MAOA (0.53) | MAOAMAOBPRKCIHSD17B1BAZ2B | |
| SCHEMBL7127913 | 0.78 | AKR1B1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018019-B2 | Estrogen receptor-modulating compounds | RADIUS PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-9954185-B2 | Organic thin film transistor, organic semiconductor thin film, and organic semiconductor material | FUJIFILM CORPORATION (JP) | 2018-04-24 | — | — | US | disclosed |
| US-20170129855-A1 | TETRAHYDRONAPHTHALENE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-05-11 | — | — | US | disclosed |
| US-20160035984-A1 | ORGANIC THIN FILM TRANSISTOR, ORGANIC SEMICONDUCTOR THIN FILM, AND ORGANIC SEMICONDUCTOR MATERIAL | FUJIFILM CORPORATION (JP) | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160035984-A1 | ORGANIC THIN FILM TRANSISTOR, ORGANIC SEMICONDUCTOR THIN FILM, AND ORGANIC SEMICONDUCTOR MATERIAL | OR10J3, SLC43A1, SLCO2A1 | MAOA 1254/4885MAOB 1937/4885PRKCI 2567/4885 |
| US-12018019-B2 | Estrogen receptor-modulating compounds | ESR2, GPER1, ESR1 | MAOA 2604/4885MAOB 2697/4885PRKCI 1471/4885 |
| US-20170129855-A1 | TETRAHYDRONAPHTHALENE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GPER1, ESR2, ESR1 | MAOA 2115/4885MAOB 2151/4885PRKCI 3103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.